Sialic acid-binding Ig-like lectin 1 (Siglec-1) mRNA (SIGLEC1 mRNA)

Sialic acid-binding Ig-like lectin 1 (Siglec-1) mRNA is the transcript encoding the CD169 protein, a type I transmembrane receptor primarily expressed on specific macrophage subsets. This mRNA is highly sensitive to Type I Interferons (IFN-α/β), and its expression levels serve as a robust surrogate marker for the Type I Interferon signature in autoimmune diseases (Rose, T., et al., 2013, Annals of the Rheumatic Diseases). In conditions such as Systemic Lupus Erythematosus (SLE) and systemic sclerosis, Siglec-1 mRNA levels in peripheral blood mononuclear cells correlate strongly with disease activity and are used to monitor therapeutic response (York, M. R., et al., 2007, Arthritis & Rheumatism). While the protein product facilitates the capture of sialylated viruses like HIV-1, the mRNA itself is a potential target for RNA interference (siRNA) or antisense oligonucleotide (ASO) therapies designed to dampen hyper-inflammatory responses (Puryear, S. B., et al., 2013, Journal of Virology). Currently, the expression of Siglec-1 mRNA is modulated by drugs that inhibit the Type I Interferon pathway, such as the IFNAR1 antagonist anifrolumab (Furie, R., et al., 2017, Science Translational Medicine). Consequently, Siglec-1 mRNA is a pivotal molecule for both diagnostic monitoring and the development of targeted immunotherapies.

Other names

CD169 mRNASialoadhesin mRNASN mRNASIGLEC-1 transcriptSialic acid-binding Ig-like lectin 1 transcript

Transcriptional downregulation via Type I Interferon receptor (IFNAR) antagonism; potential target for degradation via RNA interference (siRNA) or antisense oligonucleotides (ASO).